Clinical trials query results
From Health Canada
- Medical condition:
- MALIGNANT PLEURAL MESOTHELIOMA
- Medical condition:
- ADULT FEMALE,ADULT MALE
- Drug name:
- NINTEDANIB (BIBF 1120 ES)
- Protocol title:
- DOUBLE BLIND, RANDOMISED, MULTICENTRE, PHASE II STUDY OF NINTEDANIB IN COMBINATION WITH PEMETREXED / CISPLATIN FOLLOWED BY CONTINUING NINTEDANIB MONOTHERAPY VERSUS PLACEBO IN COMBINATION WITH PEMETREXED / CISPLATIN FOLLOWED BY CONTINUING PLACEBO MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE MALIGNANT PLEURAL MESOTHELIOMA
- Sponsor name:
- BOEHRINGER INGELHEIM (CANADA) LTD LTEE
- Date of no objection letter:
- 2013-05-24
- Control number:
- 164450
- Trial status:
- CLOSED
- Date study started:
- 2013-08-19
- Date study completed:
- 2018-11-28